Researchers at the Stanford University School of Medicine are looking for volunteers for a Phase III trial that will focus on improving a diagnostic method for Alzheimer's disease. In the study, participants will be injected with the imaging agent florbetaben before undergoing a PET scan to measure beta-amyloid plaque accumulation.

Related Summaries